The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
JAMA Dermatology · 01.03.2024 · 160 (3) · 341
DOI: 10.1001/jamadermatol.2023.5869 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.03.2024. Verfasst von ASAMI Consensus Survey Study Group und 59 weiteren Autor:innen. Beteiligte Einrichtung: Sinclair Dermatology, East Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Importance Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact.
Objective
To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI). Evidence Review A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022.
Findings
Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss. Conclusions and Relevance This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sinclair Dermatology, East Melbourne, Victoria, Australia.
- Hair Restoration Blackrock, Dublin, Ireland.
- National and International Skin Registry Solutions (NISR), Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.
- St Helens & Knowsley National Health Service Trust, St Helens, United Kingdom.
- Manchester University, Faculty of Biology, Medicine and Health, Manchester, United Kingdom.
- Netcare Greenacres Hospital, Port Elizabeth, South Africa.
Zitieren
APA
ASAMI Consensus Survey Study Group, Moussa, A., Bennett, M., Wall, D., Meah, N., York, K., Bokhari, L., Asfour, L., Rees, H., Abraham, L. S., Asz-Sigall, D., Basmanav, F. B., Bergfeld, W., Betz, R. C., Bhoyrul, B., Blume-Peytavi, U., Callender, V., Chitreddy, V., Combalia, A., …, & Takwale, A. (2024). The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology, 160(3), 341. https://doi.org/10.1001/jamadermatol.2023.5869
Vancouver
ASAMI Consensus Survey Study Group, Moussa A, Bennett M, Wall D, Meah N, York K, et al. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology. 2024;160(3):341. doi:10.1001/jamadermatol.2023.5869
BibTeX
@article{ASAMIConsensusSurveyStudyGroup2024,
author = {ASAMI Consensus Survey Study Group, ASAMI Consensus Survey Study Group and Moussa, Anthony and Bennett, Michaela and Wall, Dmitri and Meah, Nekma and York, Katherine and Bokhari, Laita and Asfour, Leila and Rees, Huw and Abraham, Leonardo Spagnol and Asz-Sigall, Daniel and Basmanav, Fitnat Buket and Bergfeld, Wilma and Betz, Regina C and Bhoyrul, Bevin and Blume-Peytavi, Ulrike and Callender, Valerie and Chitreddy, Vijaya and Combalia, Andrea and Cotsarelis, George and Craiglow, Brittany and Dhurat, Rachita and Donovan, Jeff and Doroshkevich, Andrei and Eisman, Samantha and Farrant, Paul and Ferrando, Juan and Gadzhigoroeva, Aida and Green, Jack and Grimalt, Ramon and Harries, Matthew and Hordinsky, Maria and Irvine, Alan and Jolliffe, Victoria and Kaiumov, Spartak and King, Brett and Lee, Joyce and Lee, Won-Soo and Li, Jane and Lortkipanidze, Nino and McMichael, Amy and Mesinkovska, Natasha Atanaskova and Messenger, Andrew and Mirmirani, Paradi and Olsen, Elise and Orlow, Seth J and Ovcharenko, Yuliya and Piraccini, Bianca Maria and Pirmez, Rodrigo and Rakowska, Adriana and Reygagne, Pascal and Rudnicka, Lidia and Corralo, David Saceda and Senna, Maryanne and Shapiro, Jerry and Sharma, Pooja and Siliuk, Tatiana and Starace, Michela and Suchonwanit, Poonkiat and Takwale, Anita},
title = {The Alopecia Areata Severity and Morbidity Index (ASAMI) Study},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {3},
pages = {341},
doi = {10.1001/jamadermatol.2023.5869}
}
EUVIMED